Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage
Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage
Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage
Submitted by
admin
on June 22, 2013 - 9:44am
Source:
Yahoo/BusinessWire
News Tags:
rheumatoid arthritis
Xeljanz
Pfizer
Headline:
Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Structural Damage
Do Not Allow Advertisers to Use My Personal information
